Judy Hu
Optometrist · Bowie, MDNPI 1811419450
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Aerie Pharmaceuticals, Inc. at 34.9% of the total. Reporting peaked in 2021 at $5,256 and has fallen 56.3% since, to $2,299 in 2025. Among optometrist clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $139.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$5K
- Alcon$4K
- Bausch & Lomb Americas Inc.$2K
- Thea Pharma Inc.$1K
- AbbVie$780
- Dompe US, Inc.$431
- plus $2K from 18 others
What the payments were for
- Consulting fees$2,00014%
- Speaking & faculty fees$7,42751%
- Food & beverage$5,06035%
- Gifts$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 17 | $5,070 |
| Alcon | 19 | $3,692 |
| Bausch & Lomb Americas Inc. | 11 | $1,628 |
| Thea Pharma Inc. | 7 | $1,230 |
| AbbVie(2 entities) | 16 | $780 |
| Dompe US, Inc. | 4 | $431 |
| Sun Pharmaceutical Industries Inc. | 5 | $260 |
| Glaukos Corporation | 2 | $216 |
| NEW World Medical,inc. | 1 | $201 |
| Biotissue Holdings Inc. | 2 | $168 |
| LKC Technologies, Inc. | 2 | $121 |
| Optos, Inc. | 2 | $110 |
| Amgen | 1 | $103 |
| Mallinckrodt Hospital Products Inc. | 1 | $95 |
| Sight Sciences, Inc. | 1 | $79 |
| Johnson & Johnson Vision Care, Inc. | 1 | $75 |
| Harrow Eye, LLC | 2 | $53 |
| Novartis | 3 | $52 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $36 |
| Coopervision Inc. | 1 | $35 |
| Tarsus Pharmaceuticals, Inc. | 1 | $29 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,524 in reported general payments places this provider in the 95th percentile of 790 optometrist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 283 | $153,196 |
| RhopressaNetarsudil Mesylate | 202 | $145,534 |
| CombiganBrimonidine Tartrate/Timolol | 248 | $116,024 |
| RocklatanNetarsudil Mesylat/Latanoprost | 149 | $113,350 |
| VyzultaLatanoprostene Bunod | 141 | $78,209 |
| Alphagan PBrimonidine Tartrate | 81 | $45,975 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 198 | $40,174 |
| Brimonidine Tartrate | 574 | $31,413 |
| Travoprost | 122 | $29,694 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 73 | $24,844 |
| RestasisCyclosporine | 29 | $24,179 |
| Brinzolamide | 86 | $23,240 |
| XiidraLifitegrast | 20 | $17,396 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 668 | $12,201 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 51 | $11,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $780 | $339,374641 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $5,070 | $258,884351 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $1,628 | $95,605161 claims |
| AlconSimbrinza | $3,692 | $24,84473 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 optometrist providers in Maryland.
Other optometrist in Bowie
- Susan LathropFulton$337K
- Timothy EarleyOakland$276K
- Padmini NathanFrederick$199K
- Alan GlazierRockville$87K
- Andrew MorgensternBethesda$62K
- Devin SasserSilver Spring$40K
- Rizwana IqbalEllicott City$34K
- Brian WoolfPasadena$19K
- Vickie FangGaithersburg$17K
- Aaron WeinsteinWaldorf$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.